Limits...
Cost of lifetime immunosuppression coverage for kidney transplant recipients.

Page TF, Woodward RS - Health Care Financ Rev (2008)

Bottom Line: This research estimates the impact of extending this lifetime coverage to all kidney transplant recipients on Medicare's cash flows.The study finds that extending coverage to all kidney transplant recipients would have increased Medicare's net cash outflows if the coverage were extended for patients of all income levels.There is evidence that extending coverage to only patients in the lowest income quartile could have resulted in a net cost savings to Medicare.

View Article: PubMed Central - PubMed

Affiliation: Florida International University, Miami, FL 33199, USA. tpage@fiu.edu

ABSTRACT
On January 1, 2000, Medicare extended the coverage of immunosuppression medications from 3 years to life for elderly and disabled kidney transplant recipients. This research estimates the impact of extending this lifetime coverage to all kidney transplant recipients on Medicare's cash flows. The study finds that extending coverage to all kidney transplant recipients would have increased Medicare's net cash outflows if the coverage were extended for patients of all income levels. There is evidence that extending coverage to only patients in the lowest income quartile could have resulted in a net cost savings to Medicare.

Show MeSH

Related in: MedlinePlus

Actual Graft Survival and Predicted Graft Survival Improvements for Patients in Income Quartile 1 Transplanted in 1997
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4195054&req=5

f2-hcfr-30-02-095: Actual Graft Survival and Predicted Graft Survival Improvements for Patients in Income Quartile 1 Transplanted in 1997

Mentions: Assuming that the coverage extension would have taken effect on January 1, 2000, and would have covered those who had been transplanted after January 1, 1997, we then calculated the expected change in the graft survival rates for low income patients that would have occurred with lifetime coverage. For example, in 1997 there were 636 high income ineligibles transplanted and 1,858 low income ineligibles transplanted. Assuming that the coverage increase would have caused the survival of the low income patients to track the survival for the high income patients after January 1, 2000, the Kaplan-Meier plots (Figure 2) illustrates the survival benefit for patients in income quartile 1.


Cost of lifetime immunosuppression coverage for kidney transplant recipients.

Page TF, Woodward RS - Health Care Financ Rev (2008)

Actual Graft Survival and Predicted Graft Survival Improvements for Patients in Income Quartile 1 Transplanted in 1997
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4195054&req=5

f2-hcfr-30-02-095: Actual Graft Survival and Predicted Graft Survival Improvements for Patients in Income Quartile 1 Transplanted in 1997
Mentions: Assuming that the coverage extension would have taken effect on January 1, 2000, and would have covered those who had been transplanted after January 1, 1997, we then calculated the expected change in the graft survival rates for low income patients that would have occurred with lifetime coverage. For example, in 1997 there were 636 high income ineligibles transplanted and 1,858 low income ineligibles transplanted. Assuming that the coverage increase would have caused the survival of the low income patients to track the survival for the high income patients after January 1, 2000, the Kaplan-Meier plots (Figure 2) illustrates the survival benefit for patients in income quartile 1.

Bottom Line: This research estimates the impact of extending this lifetime coverage to all kidney transplant recipients on Medicare's cash flows.The study finds that extending coverage to all kidney transplant recipients would have increased Medicare's net cash outflows if the coverage were extended for patients of all income levels.There is evidence that extending coverage to only patients in the lowest income quartile could have resulted in a net cost savings to Medicare.

View Article: PubMed Central - PubMed

Affiliation: Florida International University, Miami, FL 33199, USA. tpage@fiu.edu

ABSTRACT
On January 1, 2000, Medicare extended the coverage of immunosuppression medications from 3 years to life for elderly and disabled kidney transplant recipients. This research estimates the impact of extending this lifetime coverage to all kidney transplant recipients on Medicare's cash flows. The study finds that extending coverage to all kidney transplant recipients would have increased Medicare's net cash outflows if the coverage were extended for patients of all income levels. There is evidence that extending coverage to only patients in the lowest income quartile could have resulted in a net cost savings to Medicare.

Show MeSH
Related in: MedlinePlus